# An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet

> **NCT01342198** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pregabalin controlled release, 330 mg
- **DRUG:** Pregabalin controlled release, 330 mg
- **DRUG:** erythromycin

## Key facts

- **NCT ID:** NCT01342198
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342198, "An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01342198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*